Coherus Oncology, Inc.
General ticker "CHRS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $154.4M (TTM average)
Coherus Oncology, Inc. follows the US Stock Market performance with the rate: 52.3%.
Estimated limits based on current volatility of 3.4%: low 1.51$, high 1.62$
Factors to consider:
- Total employees count: 228 (-25.5%) as of 2024
- Top business risk factors: Regulatory and compliance, Operational and conduct risks, Fundraising challenges, Labor/talent shortage/retention, Dispute risks
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.10$, 2.83$]
- 2026-12-31 to 2027-12-31 estimated range: [1.16$, 2.88$]
Financial Metrics affecting the CHRS estimates:
- Positive: with PPE of -1.0 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 228.62 > -0.60
- Positive: Inventory ratio change, % of -13.80 <= -0.75
- Positive: 19.24 < Shareholder equity ratio, % of 23.62 <= 42.59
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term CHRS quotes
Long-term CHRS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $257.24MM | $266.96MM | $42.17MM |
| Operating Expenses | $460.44MM | $378.63MM | $223.31MM |
| Operating Income | $-203.20MM | $-111.67MM | $-181.13MM |
| Non-Operating Income | $-35.07MM | $140.17MM | $-1.99MM |
| Interest Expense | $40.54MM | $27.16MM | $9.00MM |
| R&D Expense | $109.44MM | $93.34MM | $108.89MM |
| Income(Loss) | $-238.27MM | $28.51MM | $-183.12MM |
| Taxes | $-0.38MM | $0.00MM | $0.00MM |
| Other Income(Loss) | $0.00MM | $0.00MM | $351.15MM |
| Net Income(Loss)* | $-237.89MM | $28.51MM | $168.02MM |
| Stockholders Equity | $-193.43MM | $-131.99MM | $61.01MM |
| Inventory | $62.60MM | $70.09MM | $3.17MM |
| Assets | $629.60MM | $448.53MM | $258.34MM |
| Operating Cash Flow | $-174.88MM | $-20.44MM | $-138.51MM |
| Capital expenditure | $0.29MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $144.64MM | $230.32MM | $375.09MM |
| Financing Cash Flow | $69.60MM | $-186.97MM | $-273.70MM |
| Earnings Per Share** | $-2.53 | $0.25 | $1.40 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.